


Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease (Review)

Walters JAE, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH



**THE COCHRANE
COLLABORATION®**

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2014, Issue 9

<http://www.thecochranelibrary.com>

WILEY

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON	4
BACKGROUND	6
OBJECTIVES	7
METHODS	7
Figure 1.	9
RESULTS	11
Figure 2.	14
Figure 3.	16
Figure 4.	17
Figure 5.	18
Figure 6.	19
ADDITIONAL SUMMARY OF FINDINGS	22
DISCUSSION	25
AUTHORS' CONCLUSIONS	26
ACKNOWLEDGEMENTS	26
REFERENCES	26
CHARACTERISTICS OF STUDIES	31
DATA AND ANALYSES	69
Analysis 1.1. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 1 Treatment failure.	74
Analysis 1.2. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 2 Rate of relapse to 30 days.	75
Analysis 1.3. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 3 Relapse.	76
Analysis 1.4. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 4 Mortality.	77
Analysis 1.5. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 5 Early FEV1 (L) - absolute or change.	78
Analysis 1.6. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 6 Early FEV1 (% predicted).	79
Analysis 1.7. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 7 Early FVC (L) - absolute or change.	80
Analysis 1.8. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 8 Early FVC (% predicted).	81
Analysis 1.9. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 9 Early FEV1/FVC (%).	81
Analysis 1.10. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 10 Early PEF (L/minute) - absolute or change.	82
Analysis 1.11. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 11 Early dyspnoea score.	83
Analysis 1.12. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 12 Early PaO2 (mmHg) - absolute or change.	84
Analysis 1.13. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 13 Early PaCO2 (mmHg) - absolute or change.	85
Analysis 1.14. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 14 FEV1 (L) - absolute or change.	86
Analysis 1.15. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 15 FEV1 (% predicted).	87
Analysis 1.16. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 16 FVC (L) - absolute or change.	88
Analysis 1.17. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 17 FVC (% predicted).	88
Analysis 1.18. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 18 FEV1/FVC (%).	89
Analysis 1.19. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 19 PEF (L/minute) - absolute.	90
Analysis 1.20. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 20 Transitional dyspnoea index (change).	91
Analysis 1.21. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 21 Dyspnoea score walking (change, VAS).	91
Analysis 1.22. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 22 Overall dyspnoea score.	92

Analysis 1.23. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 23 PaO2 (mmHg) - change or absolute.	93
Analysis 1.24. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 24 PaCO2 (mmHg) - absolute.	94
Analysis 1.25. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 25 Overall quality of life score (CRQ) (change).	95
Analysis 1.26. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 26 Physical capacity (m) (6-minute walk distance).	95
Analysis 1.27. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 27 Length of stay (days).	96
Analysis 1.28. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 28 Duration of mechanical ventilation (days).	97
Analysis 1.29. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 29 Adverse drug effects.	98
Analysis 1.30. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 30 Adverse effect - hyperglycaemia (30 days).	99
Analysis 1.31. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 31 Adverse effect - hypertension.	100
Analysis 1.32. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 32 Adverse effect - gastrointestinal bleeding.	101
Analysis 1.33. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 33 Adverse effect - dyspepsia.	101
Analysis 1.34. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 34 Adverse effect - weight gain.	102
Analysis 1.35. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 35 Adverse effect - depression.	103
Analysis 1.36. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 36 Adverse effect - anxiety.	103
Analysis 1.37. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 37 Adverse effect - psychiatric disorder.	104
Analysis 1.38. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 38 Adverse effect - insomnia.	105
Analysis 1.39. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 39 Adverse effect - delirium.	105
Analysis 1.40. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 40 Adverse effect - secondary infection.	106
Analysis 1.41. Comparison 1 Systemic corticosteroid (SCS) versus placebo, Outcome 41 Adverse effect - ventilator-associated pneumonia.	106
Analysis 2.1. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 1 Treatment failure.	107
Analysis 2.2. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 2 Relapse.	108
Analysis 2.3. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 3 Mortality after discharge (1-3 months).	109
Analysis 2.4. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 4 Early FEV1 (L).	109
Analysis 2.5. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 5 Early FVC (L).	110
Analysis 2.6. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 6 Early dyspnoea score (VAS).	110
Analysis 2.7. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 7 Early cough score (VAS).	111
Analysis 2.8. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 8 Early sputum volume score (VAS).	111
Analysis 2.9. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 9 FEV1 (L) - absolute or change.	112
Analysis 2.10. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 10 FVC (L) - absolute.	113
Analysis 2.11. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 11 FEV1/FVC ratio.	113
Analysis 2.12. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 12 Dyspnoea score (VAS) at 7-10 days.	114
Analysis 2.13. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 13 Cough score (VAS) at 7 days.	114

Analysis 2.14. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 14 Sputum volume score (VAS) at 7 days.	115
Analysis 2.15. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 15 PaO ₂ (mmHg) at 7 days.	115
Analysis 2.16. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 16 PaCO ₂ (mmHg) at 7 days.	116
Analysis 2.17. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 17 Health status: Clinical COPD Questionnaire (change at 1 week).	116
Analysis 2.18. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 18 Quality of life: SGRQ (change at 7 days).	117
Analysis 2.19. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 19 Quality of life: CRQ Dyspnoea (change at 4 weeks).	117
Analysis 2.20. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 20 Quality of life: CRQ Fatigue (change at 4 weeks).	118
Analysis 2.21. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 21 Quality of life: CRQ Mastery (change at 4 weeks).	118
Analysis 2.22. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 22 Quality of life: CRQ Emotion (change at 4 weeks).	119
Analysis 2.23. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 23 Duration of hospitalisation (days).	119
Analysis 2.24. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 24 Adverse effect - hyperglycaemia.	120
Analysis 2.25. Comparison 2 Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS), Outcome 25 Adverse effect - hypertension.	120
ADDITIONAL TABLES	120
APPENDICES	127
WHAT'S NEW	128
HISTORY	129
CONTRIBUTIONS OF AUTHORS	130
DECLARATIONS OF INTEREST	130
SOURCES OF SUPPORT	130
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	130
INDEX TERMS	131

[Intervention Review]

Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease

Julia AE Walters¹, Daniel J Tan¹, Clinton J White¹, Peter G Gibson², Richard Wood-Baker¹, E. Haydn Walters³

¹School of Medicine, University of Tasmania, Hobart, Australia. ²Department of Respiratory and Sleep Medicine, John Hunter Hospital, New Lambton, Australia. ³NHMRC CRE for Chronic Respiratory Disease, School of Medicine, University of Tasmania, Hobart, Australia

Contact address: Julia AE Walters, School of Medicine, University of Tasmania, MS1, 17 Liverpool Street, PO Box 23, Hobart, Tasmania, 7001, Australia. Julia.Walters@utas.edu.au.

Editorial group: Cochrane Airways Group.

Publication status and date: New search for studies and content updated (conclusions changed), published in Issue 9, 2014.

Review content assessed as up-to-date: 23 May 2014.

Citation: Walters JAE, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2014, Issue 9. Art. No.: CD001288. DOI: 10.1002/14651858.CD001288.pub4.

Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Acute exacerbations of chronic obstructive pulmonary disease (COPD) are a major cause of hospital admission and mortality. They contribute to long-term decline in lung function, physical capacity and quality of life. The most common causes are infective, and treatment includes antibiotics, bronchodilators and systemic corticosteroids as anti-inflammatory agents.

Objectives

To assess the effects of corticosteroids administered orally or parenterally for treatment of acute exacerbations of COPD, and to compare the efficacy of parenteral versus oral administration.

Search methods

We carried out searches using the Cochrane Airways Group Specialised Register of Trials, MEDLINE and CENTRAL (Cochrane Central Register of Controlled Trials), and checked references of included studies and trials registries. We conducted the last search in May 2014.

Selection criteria

Randomised controlled trials comparing corticosteroids administered orally or parenterally with an appropriate placebo, or comparing oral corticosteroids with parenteral corticosteroids in the treatment of people with acute exacerbations of COPD. Other interventions (e.g. bronchodilators and antibiotics) were standardised for both groups. We excluded clinical studies of acute asthma.

Data collection and analysis

We used standard methodological procedures expected by The Cochrane Collaboration.

Main results

Sixteen studies (n = 1787) met inclusion criteria for the comparison systemic corticosteroid versus placebo and 13 studies contributed data (n = 1620). Four studies (n = 298) met inclusion criteria for the comparison oral corticosteroid versus parenteral corticosteroid and three studies contributed data (n = 239). The mean age of participants with COPD was 68 years, median proportion of males 82% and mean forced expiratory volume in one second (FEV₁) per cent predicted at study admission was 40% (6 studies; n = 633). We judged risk of selection, detection, attrition and reporting bias as low or unclear in all studies. We judged risk of performance bias high in one study comparing systemic corticosteroid with control and in two studies comparing intravenous corticosteroid versus oral corticosteroid.

Systemic corticosteroids reduced the risk of treatment failure by over half compared with placebo in nine studies (n = 917) with median treatment duration 14 days, odds ratio (OR) 0.48 (95% confidence interval (CI) 0.35 to 0.67). The evidence was graded as high quality and it would have been necessary to treat nine people (95% CI 7 to 14) with systemic corticosteroids to avoid one treatment failure. There was moderate-quality evidence for a lower rate of relapse by one month for treatment with systemic corticosteroid in two studies (n = 415) (hazard ratio (HR) 0.78; 95% CI 0.63 to 0.97). Mortality up to 30 days was not reduced by treatment with systemic corticosteroid compared with control in 12 studies (n = 1319; OR 1.00; 95% CI 0.60 to 1.66).

FEV₁, measured up to 72 hours, showed significant treatment benefits (7 studies; n = 649; mean difference (MD) 140 mL; 95% CI 90 to 200); however, this benefit was not observed at later time points. The likelihood of adverse events increased with corticosteroid treatment (OR 2.33; 95% CI 1.59 to 3.43). Overall, one extra adverse effect occurred for every six people treated (95% CI 4 to 10). The risk of hyperglycaemia was significantly increased (OR 2.79; 95% CI 1.86 to 4.19). For general inpatient treatment, duration of hospitalisation was significantly shorter with corticosteroid treatment (MD -1.22 days; 95% CI -2.26 to -0.18), with no difference in length of stay the intensive care unit (ICU) setting.

Comparison of parenteral versus oral treatment showed no significant difference in the primary outcomes of treatment failure, relapse or mortality or for any secondary outcomes. There was a significantly increased rate of hyperglycaemia in one study (OR 4.89; 95% CI 1.20 to 19.94).

Authors' conclusions

There is high-quality evidence to support treatment of exacerbations of COPD with systemic corticosteroid by the oral or parenteral route in reducing the likelihood of treatment failure and relapse by one month, shortening length of stay in hospital inpatients not requiring assisted ventilation in ICU and giving earlier improvement in lung function and symptoms. There is no evidence of benefit for parenteral treatment compared with oral treatment with corticosteroid on treatment failure, relapse or mortality. There is an increase in adverse drug effects with corticosteroid treatment, which is greater with parenteral administration compared with oral treatment.

PLAIN LANGUAGE SUMMARY

Do systemic corticosteroids improve treatment outcomes in flare-ups of chronic obstructive pulmonary disease?

Why is this question important?

Chronic obstructive pulmonary disease (COPD), also referred to as emphysema or chronic bronchitis, is a long-term lung condition commonly associated with smoking. People with COPD usually have persistent symptoms of breathlessness and may experience flare-ups (exacerbations) on occasion, often precipitated by infection, in which symptoms become markedly worse and further medical intervention is required beyond regular treatment by inhalers.

Systemic (i.e. not inhaled corticosteroids) such as prednisolone, prednisone and cortisone, are anti-inflammatory drugs commonly used in the treatment of exacerbations. We wanted to assess the effectiveness of systemic corticosteroids and whether different routes of administration have impacts on response to treatment of COPD exacerbations.

How did we answer the question?

We looked for all studies that compared corticosteroid, given either by injections (parenterally) or tablets (orally), with matching dummy injections or tablets and all studies that compared corticosteroid given by injections with corticosteroid given by tablets.

What did we find?

We found 16 studies including over 1700 people with COPD who experienced a flare-up that required additional medical treatment that compared corticosteroid given by injections or tablets with dummy treatment. Four studies with nearly 300 people compared corticosteroid injections with corticosteroid tablets. More men than women took part in the studies and they were usually in their late 60s, with moderately severe symptoms of COPD. Most studies took place in hospitals, two in intensive care units with people who needed breathing support, and three studies involved people who were treated at home. The last search for studies to include in the review was done in May 2014.

There were three studies where people knew which treatment they were getting, but otherwise studies were generally well designed.

People treated with either corticosteroid injections or tablets compared with dummy treatment were less likely to experience treatment failure, 122 fewer people per 1000 treated, with a lower rate of relapse by one month. They had shorter stays in hospital if they did not require assisted ventilation in an intensive care unit, and their lung function and breathlessness improved more quickly during treatment. However, they had more adverse events while taking treatment, especially a temporary increase in glucose levels in blood. Corticosteroid treatment did not reduce the number of people who died within one month of their flare-up.

In studies comparing two ways of giving corticosteroid, either by injections or tablets, there were no differences in treatment failure, the time in hospital or number of deaths after discharge; however, a temporary increase in glucose levels in blood was more likely with injections than tablets.

Conclusion

There is high-quality evidence that is unlikely to be changed by future research that people who experience flare-ups of COPD benefit from treatment with corticosteroid given by injections or tablets with the increased risk of some temporary side effects.

SUMMARY OF FINDINGS FOR THE MAIN COMPARISON *[Explanation]*

Systemic corticosteroid compared with placebo for acute exacerbations of COPD						
Patient or population: acute exacerbations COPD Settings: outpatient, inpatient and people in ICU Intervention: systemic corticosteroid Comparison: placebo						
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Systemic corticosteroid					
Treatment failure Need to intensify therapy/ ED or hospital admission Follow-up: 3-30 days	276 per 1000	154 per 1000 (118 to 203)	OR 0.48 (0.35 to 0.67)	917 (9 studies)	⊕⊕⊕⊕ high	-
Relapse Treatment for AE of COPD or hospital re-admission Follow-up: 1-4 months	215 per 1000	174 per 1000 (122 to 242)	OR 0.77 (0.51 to 1.17)	596 (5 studies)	⊕⊕⊕○ moderate ¹	In 2 studies (n = 415) relapse to 1 month was lower with systemic corticosteroid compared with placebo (HR 0.78; 95% CI 0.63 to 0.97)
Improvement in lung function - early effect FEV ₁ (L) as absolute or change Follow-up: 3 days	The mean FEV ₁ in control groups ranged from 0.77 to 0.91 L	The mean early improvement in lung function in the intervention group was 0.14 L higher (0.09 to 0.20 higher)	-	649 (7 studies)	⊕⊕⊕⊕ high	-

Decreased breathlessness - early effect Borg scale or VAS Follow-up: 3 days	The mean change in breathlessness in control group was 1.8 units using the Borg scale and 1.5 units on the VAS scale	The mean early decrease in breathlessness in the intervention group was 0.35 standard deviations higher (0.05 to 0.64 higher)	-	178 (3 studies)	⊕⊕⊕○ moderate ²	Effect size on Borg scale 0.93 units; 95% CI 0.18 to 1.7 (MCID = 2); effect size on VAS scale 5.24; 95% CI 0.75 to 9.59 (MCID = 10)
Adverse drug effect Follow-up: 2-26 weeks	285 per 1000	481 per 1000 (388 to 577)	OR 2.33 (1.59 to 3.43)	736 (8 studies)	⊕⊕⊕⊕ high	-
Hyperglycaemia	124 per 1000	282 per 1000 (208 to 371)	OR 2.79 (1.86 to 4.19)	804 (6 studies)	⊕⊕⊕⊕ high	-

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

AE: acute exacerbation; **CI:** confidence interval; **COPD:** chronic obstructive pulmonary disease; **ED:** emergency department; **FEV₁:** forced expiratory volume in 1 second; **HR:** hazard ratio; **MCID:** minimum clinically important difference; **OR:** odds ratio; **VAS:** visual analogue scale.

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

¹ Wide CIs include significant benefit and harm (-1 for imprecision).

² Upper or lower CI of effect size crosses 0.5 (-1 for imprecision).

To keep the file size to a minimum, this document contains only the Abstract and Plain Language Summary for the Cochrane Review, which should be sufficient for the purpose of rating it for Relevance and Newsworthiness. If you wish to view the entire document, please return to the rating page and choose the "Additional Info" link directly under the "View Article" link. Please note the file may be quite large.